cosibelimab-ipdl (Unloxcyt)

Indications

• treatment of adults with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation therapy

Contraindications

• pregnancy

Dosage

• 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks

Injection: 300 mg/5 mL (60 mg/mL) solution in a single-dose vial

Adverse effects

• >= 10%
  • fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, localized infection, urinary tract infection
• Immune-Mediated Adverse Reactions

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• programmed death ligand-1 (PD-L1) blocking antibody

More general terms

• antineoplastic monoclonal antibody